A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-Dopa Induced Dyskinesias in Parkinson's Patients With Severe L-Dopa Induced Dyskinesias.

Trial Profile

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-Dopa Induced Dyskinesias in Parkinson's Patients With Severe L-Dopa Induced Dyskinesias.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2012 Planned number of patients (40) added as reported by European Clinical Trials Database
    • 11 Apr 2011 Results published in the Movement Disorders.
    • 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top